In the United States will be able to use tenofovir for the treatment of hepatitis B in children

The Food and Drug Administration (FDA) has supported Gilead, the manufacturer of the drug Viread (tenofovir disoproxil fumarate), in support of the drug. The regulator has approved the use of drugs for the treatment of hepatitis B among children from two years.

According to experts, the effectiveness of the drug was confirmed by clinical studies with the participation of 89 patients with hepatitis B (HBeAg-positive) aged up to twelve years.

According to published results, after 48 weeks of therapy, 77% of volunteers had a virus level in the blood of less than 400 cop / ml. At the same time, in the placebo group, this indicator was only in 7%.

In 66% of patients, ALT was normalized, seroconversion to HBeAg was found in a quarter of the subjects.

We add that tenofovir disoproxil fumarate (TDF) is a nucleoside reverse transcriptase inhibitor (NRTI) intended for the treatment of HIV infection and hepatitis B. A more secure version of the product, tenofovir alafenamide (TAF), is also widely used now.